Discounted Cash Flow (DCF) Analysis Levered

Aptevo Therapeutics Inc. (APVO)

$ 16.75
-0.15 (-0.89%)

Free Cash Flow

Year
A/P
2016
Actual
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue 36.4314.6623.0732.424.313.793.332.922.572.26
Revenue (%)
Operating Cash Flow -36.86-41.57-51.42-42.38-29.32-10.74-9.44-8.29-7.29-6.40
Operating Cash Flow (%)
Capital Expenditure -2.51-1.40-0.98-0.15-0.09-0.18-0.15-0.14-0.12-0.10
Capital Expenditure (%)
Free Cash Flow -39.37-42.98-52.40-42.54-29.41-10.92-9.59-8.43-7.41-6.51

Weighted Average Cost Of Capital

Share price $ 16.75
Beta 7.058
Diluted Shares Outstanding 3.23
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt 5.00%
Risk-Free Rate
Market Risk Premium
Cost of Equity 58.645
Total Debt 10
Total Equity 54.15
Total Capital 64.15
Debt Weighting 15.59
Equity Weighting 84.41
Wacc

Build Up Free Cash Flow

Year
A/P
2016
Actual
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue 36.4314.6623.0732.424.313.793.332.922.572.26
Operating Cash Flow -36.86-41.57-51.42-42.38-29.32-10.74-9.44-8.29-7.29-6.40
Capital Expenditure -2.51-1.40-0.98-0.15-0.09-0.18-0.15-0.14-0.12-0.10
Free Cash Flow -39.37-42.98-52.40-42.54-29.41-10.92-9.59-8.43-7.41-6.51
WACC
PV LFCF -7.27-4.25-2.48-1.45-0.85
SUM PV LFCF -16.30

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 50.28
Free cash flow (t + 1) -6.77
Terminal Value -14.62
Present Value of Terminal Value -1.91

Intrinsic Value

Enterprise Value -18.21
Net Debt -29.98
Equity Value 11.77
Shares Outstanding 3.23
Equity Value Per Share 3.64